Management of Acute Myeloid Leukemia (AML) in Older Patients.
Publication/Presentation Date
7-28-2020
Abstract
PURPOSE OF REVIEW: The acute myeloid leukemia (AML) treatment landscape has rapidly evolved over the past few years. These changes have several implications for the care of older adults (≥ 60 years), who have inferior clinical outcomes. We review decision-making in older adults, focusing on patient- and disease-related factors. We then summarize current treatment options, including multiple recently approved therapies, based on hypothetical clinical scenarios.
RECENT FINDINGS: In lieu of using chronological age to determine fitness, we highlight the importance of standardized fitness assessments using geriatric assessments. Next, we review intensive and lower-intensity treatment options in the upfront setting. We focus on multiple newly approved medications, including venetoclax, midostaurin, CPX-351, gemtuzumab, glasdegib, enasidenib, and ivosidenib, and their specific indications. Lastly, we briefly discuss supportive care of older adults with AML. Outcomes of older adults with AML remain poor; fortunately, there are many new promising treatment options. Personalized treatment plans based on patient- and disease-specific factors are essential to the care of older adults with AML.
Volume
22
Issue
10
First Page
103
Last Page
103
ISSN
1534-6269
Published In/Presented At
Abdallah, M., Xie, Z., Ready, A., Manogna, D., Mendler, J. H., & Loh, K. P. (2020). Management of Acute Myeloid Leukemia (AML) in Older Patients. Current oncology reports, 22(10), 103. https://doi.org/10.1007/s11912-020-00964-1
Disciplines
Medicine and Health Sciences
PubMedID
32725515
Department(s)
Department of Medicine, Cardiology Division
Document Type
Article